Synapse - Gail Alicia Panton

Gail Alicia Panton

Research Focus

Nursing; Clinical Trials Nurse IV

Recent additions – View all

Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
Meeting Abstract

Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
Blood (2024)

Fulltext@MSK | Save
A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
Meeting Abstract

Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
Blood (2023)

Fulltext@MSK | Save
Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
Journal Article

Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Co-authors at MSK

Types of Work

Publications